Processa Pharmaceuticals Inc

PCSA

Company Profile

  • Business description

    Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

  • Contact

    7380 Coca Cola Drive
    Suite 106
    HanoverMD21076
    USA

    T: +1 443 776-3133

    https://www.processapharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,822.503.90-0.04%
CAC 407,723.4727.200.35%
DAX 4024,073.67286.221.20%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,806.5316.38-0.19%
HKSE24,073.04185.210.78%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,650.9863.300.16%
NZX 50 Index12,798.4633.510.26%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,582.307.00-0.08%
SSE Composite Index3,493.1620.040.58%

Market Movers